Responding to an increase in demand for its expert regulatory services, leading pharmaceutical and biotech product development consultancy Boyds has made two key hires to its Regulatory Affairs team.
Dr Victoria Marsh joins the company as Director of Regulatory Affairs and Dr Kim Champion as Regulatory Affairs Manager.
A specialist in molecular biology and protein biochemistry, Victoria has extensive regulatory experience across the full clinical product lifecycle from Phase 1 clinical trials through to licence maintenance for marketed products. She has worked with and for companies…
Cambridge UK – 15 April 2020 – Healx, the AI-powered and patient-inspired tech company specialising in accelerating the discovery and development of rare disease treatments, today announced a partnership with US and Europe-based patient group Children’s Tumor Foundation (CTF) to progress new AI-derived therapies for neurofibromatosis (NF).
NF is a rare genetic disorder that affects 1 in 3,000 people worldwide. Currently, no treatments exist for any of the three types of NF (NF1, NF2 and schwannomatosis). Healx will combine its AI technology and drug discovery expertise with the disease data,…
Cambridge, UK, 14 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The CHOSOURCE platform includes a gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS…
Applications for Accelerate@Babraham, designed to support early stage life science ventures, will close on June 17th 2020.
The Accelerate@Babraham initiative is designed to support ambitious early stage life science ventures. It does this by giving access to appropriate short-term open access laboratory and office space, facilitating interaction with the academic community at the Babraham Institute and providing access to our global network, including mentoring and business support.
A key activity within the Accelerate@Babraham initiative is the annual StartUP@Babraham competition. The…
Hints and Tips for Working from Home by george james ltd
Working from home is a new experience for many people, and even those of us who have worked at home on and off for many years have probably not done so for such an extended period. For some people working at home may become the new norm.
george james ltd have put together some hints and tips that we hope you find helpful.
By visiting the knowledge base section of our website you can find links to 2 videos and one downloadable aide-memoir: http://georgejamesltd.com/free-knowledge-base/training-and-development/
Video1: 10 Tips for…
Cambridge, UK: 14 April 2020: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, announces that Regeneron Pharmaceuticals Inc (“Regeneron”) has been unsuccessful in recent attempts to invalidate four of Kymab’s US patents covering genetically modified mice and the human antibody therapeutics produced from these mice. The patents are US patent numbers 9,434,782; 9,505,827; 9,447,177; and 10,165,763 known as the “Bradley Patents”. Equivalent patents have been granted by the European Patent Office and in other jurisdictions including Japan…
New England Biolabs is working diligently to ensure we keep our employees and their families safe, while maintaining our business continuity in support of our many customers around the globe. Our manufacturing and distribution teams continue to be fully operational, and we are working closely with our suppliers and distribution partners to ensure uninterrupted access to our products and technical support. We are also following the guidelines of local and national health organizations in order to mitigate the spread of COVID-19. If you have any questions or concerns, please feel free to…
The MagSi-NA Pathogens Kit from AMSBIO enables easy extraction of DNA and RNA from serum, plasma, oropharyngeal swab / nasopharyngeal swab, and any other respiratory samples for pathogen detection.The kit is particularly suitable for total nucleic acid extraction for SARS-CoV-2 / COVID-19 detection, currently a major bottleneck in COVID-19 testing.Due to the kit’s simple protocol and ready-to-use-agents, it is easy to scale to small, medium, and high-throughput automation, yielding highly pure nucleic acid in small elution volumes. The MagSi-NA…
Dear Friends, Colleagues and Supporters of NHS staff, We are seeking donations to the Cambridge China COVID-19 Collaboration (4C) Appeal which is an official part of the University of Cambridge COVID-19 appeal.
This appeal is led by two doctors and University of Cambridge Professors, Toni Vidal Puig and Sadaf Farooqi. Our aim is to ensure that high-grade Personal Protective Equipment (PPE) is available for health and social care professionals, caring for patients with COVID-19 in Cambridge and the East of England. We want to guarantee the safety and protection of our staff on the…
Cambridge, UK, 07 April 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has contributed to two new peer-reviewed papers under the U.S. Food and Drug Administration’s (FDA) CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative. The papers, in Nature Scientific Reports1 and Toxicology and Applied Pharmacology2, focus on application of improved cardiac safety testing protocols and recommendations for best practice for the drug discovery industry.
The CiPA Initiative (www.cipaproject.org), which began in July 2013…